肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, tainan. what...
TRANSCRIPT
![Page 1: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/1.jpg)
肺高壓的診斷與治療
國立成功大學附設醫院許志新 醫師
2012/05/26, Tainan
![Page 2: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/2.jpg)
What is PH ? What is PAH ?
![Page 3: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/3.jpg)
Pulmonary Hypertension
Pulmonary hypertension is defined as an increase in mean pulmonary artery pressure 25 mmHg at rest≧
Pulmonary hypertension is a hemodynamic and pathophysiological state that can be found in multiple clinical condition
![Page 4: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/4.jpg)
1. Pulmonary arterial hypertension
• 1.1Idiopathic PAH
• 1.2 Heritable
• 1.3 Drugs and toxin related
• 1.4 Associated with (APAH) 1.4.1 Connective tissue diseases
1.4.2 HIV 1.4.3 Portal hypertension 1.4.4 Congenital heart diseases 1.4.5 Schistosomiasis
1.4.6 Chronic haemolytic anaemia
• 1.5 Persist PH of the newborn
1’ Pulmonary veno-occlusive disease
3. PH with Lung Diseases/Hypoxemia
• 3.1 COPD
• 3.2 Interstitial lung diseases
3.3 mixed restrictive and obstructive pattern
• 3.4 Sleep-disordered breathing
3.5 Alveolar hypoventilation disorders
3.6 Chronic exposure to high altitude
• 3.7 Developmental abnormalities
4. Chronic thromboembolicPH • TE obstruction of proximal PA • TE obstruction of distal PA • Non thrombotic P embolism
5. PH with unclear and /or
multifactorial mechanisms
Dana Point 2008
Pulmonary Arterial Hypertension Diagnostic Classification
2. PH with left heart disease • 2.1 Systolic dysfunction • 2.2 Diastolic dysfunction 2.3 Valvular disease
![Page 5: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/5.jpg)
Pulmonary Arterial Hypertension
Pulmonary hypertension Elevated pressure in the pulmonary vascular bed,
without specify the location of the pathology
Pulmonary arterial hypertension Elevated pressure in the pulmonary vascular bed,
specially ascribed to pathology in the pulmonary arterial tree.
![Page 6: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/6.jpg)
Definition of PAH by WHO
Mean PAP > 25mmHg at rest
PAWP < 15 mmHg
![Page 7: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/7.jpg)
What do we face ?
Rare Miss diagnosis Rapid progress Poor prognosis
![Page 8: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/8.jpg)
Really rare ? Or Under diagnosis?
![Page 9: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/9.jpg)
Prevalence of PAH
![Page 10: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/10.jpg)
PAH is a rare disease: Prevalence of PAH
France: – 15 cases/million
England and Wales:– Severe PAH: 30–50 cases/million
Estimated prevalence of 120,000 pts with PAH in theUSA, EU, Canada and Japan.- US 50,000 to 100,000- 15,000 to 25,000 diagnosed and treated
Estimated 260,000 pts hospitalized/year with all cause PH in USA (medicare database)
Humbert, et al. Am J Resp Crit Care Med 2006; 173: 1023–30 Peacock. BMJ 2003; 326: 835–6 Link J. Chest 2011; 139:497-504.Gomberg-Maitland M. Chest 2011;139:482-483
![Page 11: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/11.jpg)
Prevalence of PAH in Associated Conditions
Associated Condition Prevalence of PAHSystemic sclerosis 7-12 %
HIV infection 0.46-0.5 %
Portal hypertension 2-6 %
Congenital heart disease 1.6-12.5 per million in those with congenital systemic-to-pulmonary shunts → 25-50 % affected by Eisenmenger syndrome
Schistosomiasis 4.6 % in those with hepatosplenic disease
Chronic hemolytic anemia Highly variable; currently being studied
Simonneau, et al. J Am Coll Cardiol. 2009;54(1):S43-54.Simonneau, et al. J Am Coll Cardiol. 2009;54(1):S43-54.
![Page 12: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/12.jpg)
NORMAL REVERSIBLE DISEASE IRREVERSIBLE DISEASE
Pathogenesis of Pulmonary ArterialPathogenesis of Pulmonary ArterialHypertensionHypertension
![Page 13: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/13.jpg)
PAH: Pathophysiology
Pulmonary vessel
remodeling
Pulmonary vascular
resistance increase
RV remodeling
RV dysfunction
![Page 14: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/14.jpg)
Do we have a luxury time ?
![Page 15: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/15.jpg)
IPreclinical /
no symptoms
IISymptomatic /
stable
IIIProgression /
declining
Pulm. pressure
Cardiac outputLev
el
Time
Years Months
Therapeutic window
PAH: a rapidly evolving disease
RV function
![Page 16: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/16.jpg)
Severity of Pulmonary Hypertension
Degree of disease
– Mild
– Moderate
– Severe
Mean PAP (mmHg)
– 25 - 40
– 41 - 55
– >55
![Page 17: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/17.jpg)
NYHA/WHO classification of functional status
Class Description
IPatients with pulmonary hypertension in whom there is no limitation of usual physical activity: ordinary physical activity does not cause increased dyspnoea, fatigue, chest pain or pre-syncope
IIPatients with pulmonary hypertension who have mild limitation of physical activity. There is no discomfort at rest but normal physical activity causes increased dyspnoea, fatigue, chest pain or pre-syncope
IIIPatients with pulmonary hypertension who have a marked limitation of physical activity. There is no discomfort at rest but less than ordinary activity causes increased dyspnoea, fatigue, chest pain or pre-syncope
IV
Patients with pulmonary hypertension who are unable to perform any physical activity and who may have signs of right ventricular failure at rest. Dyspnoea and/or fatigue may be present at rest and symptoms are increased by almost any physical activity
1. Barst RJ et al. J Am Coll Cardiol 2004 16; 43 (12 Suppl S): 40S–47S
![Page 18: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/18.jpg)
Brenot F. Chest 1994; 105: 33S–36S
0 12 24 36 48 60 72 84 960
25
50
75
100
WHO class I – II (n = 30)
WHO class III – IV (n = 75)
Months
Su
rviv
al (
%)
Early diagnosis of PAH and early intervention improves survival prospects
PAH progresses rapidly if left untreated... even in mildly symptomatic disease
![Page 19: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/19.jpg)
Prognosis of Pulmonary Hypertension
Survival years
![Page 20: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/20.jpg)
Early diagnosis is important, but is it easy ?
![Page 21: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/21.jpg)
24%
63%
12%
1%0%
10%
20%
30%
40%
50%
60%
70%
80%
Class I Class II Class III Class IV
n = 674
Humbert M, et al. Am J Resp Crit Care Med 2006; 173: 1023–30
PAH is still often diagnosed late:French National Registry 2002–2003
![Page 22: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/22.jpg)
Symptoms
– Symptoms may include:• Dyspnea ● Fatigue• Syncope ● Edema• Dizziness ● Chest Pain
– Non-specific nature of complaint can lead to:• Misdiagnosis • Delayed diagnosis ( It takes an average of 3 years from
first symptoms to diagnosis )
![Page 23: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/23.jpg)
Why is missed?
Young patient with non specific symptom with “normal” CXR and EKG
Lack of practical therapy in the earlier era lead to therapeutic nihilism
Co-mobid condition have similar symptoms
![Page 24: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/24.jpg)
Progressive Dyspnea Pedal edema Non-productive
Cough Fatigue Syncope Chest Pain
85%
30% 19% 13% 12% 7%
SuspectPAH: Clinical Presentation
![Page 25: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/25.jpg)
Reason to suspect PAH
Unexplained dyspnea Typical symptom with signs “At risk“ condition CREST, liver disease, HIV, sickle cell Family history of PAH History of stimulant/anorexigen drug use
![Page 26: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/26.jpg)
How to I know the patient really got PAH?
![Page 27: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/27.jpg)
Diagnosis of PAH: a four-stage process
Galiè N et al Eur Heart J 2004; 25: 2243–2278
1. Suspicion of pulmonary
hypertension 2. Detection of pulmonary
hypertension
3. Pulmonary hypertension
class identification
4. Pulmonary arterial
hypertension evaluation
•Symptoms and physical examination
•Screening procedures
•Incidental findings
•Electrocardiogram
•Chest radiograph
•Transthoracic Dopplerechocardiography
•Pulmonary function tests and arterial blood gases
•Ventilation/perfusion lung scan
•High-resolution CT
•Spiral CT
•Pulmonary angiography
•Type (blood tests and immunology, HIV test, abdominal ultrasound)
•Exercise capacity (6MWD, peak oxygen consumption)
•Haemodynamics (right- heart catheterisation)
![Page 28: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/28.jpg)
Case2006/03/11
21 y/o female Dyspnea and fatigue for about several
months Visited LMD for help but in vain Condition get worse and worse----
![Page 29: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/29.jpg)
NCKUH ER
Physical examination BP: 150/80 mmHg, HR: 120 bpm, RR: 24/min, SaO2:
90% Lip: mild cyanotic change Jugular vein enlargement Breathing sound: clear Heart : tachycardia, fix split S2 , increased P2, systolic
murmur GrIV/VI over LLSB, RV heave (+) Extremities: warm, mild edema. ABG: PaO2: 52mmHg
![Page 30: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/30.jpg)
Electrocardiography
Sinus tachycardia
RAD
RVH
![Page 31: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/31.jpg)
CXR
Cardiomegaly C/T ratio: 0.59 Dilated pulmonary trunk
![Page 32: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/32.jpg)
Echocardiography
Dilated RA,RV. RV hypertrophy Adequate LV performance. Moderate to severe TR with
Pul.HTN <systolic PAP= 140mmHg>
![Page 33: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/33.jpg)
Pulmonary hypertension with right heart failure was suspected, R/O pulmonary embolism, R/O congenital heart disease, R/O primary pulmonary hypertension
Admitted to CCU for further care
![Page 34: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/34.jpg)
Chest CT
Dilated pulmonary trunk and pulmonary artery
No evidence of pulmonary embolism
No evidence of lung disease
![Page 35: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/35.jpg)
TEE: No congenital heart disease Autoimmune screen: Normal HIV: Negative Pregnancy test : Negative
![Page 36: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/36.jpg)
Diagnosis
Primary pulmonary hypertension was impressed. (WHO FC IV)
![Page 37: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/37.jpg)
How long do I have ? How can I do ?
Could you help me ?
![Page 38: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/38.jpg)
How can your patient do ?
![Page 39: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/39.jpg)
PAH Therapy: Life style considerations
Sodium restriction
Abstinence from smoking
Avoid high altitude
• <4,000 feet above sea level
Avoid physical exertion in setting of pre- or frank
syncope
Avoid pregnancy
Immunization for illnesses (Influenza and
pneumococcal vaccination)
![Page 40: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/40.jpg)
![Page 41: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/41.jpg)
Could we help patient ?
![Page 42: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/42.jpg)
Goals of Therapy
Alleviate symptoms, improve exercise capacity and quality of life
Improve cardiopulmonary hemodynamics and prevent right heart failure
Delay time to clinical worsening Reduce morbidity and mortality
![Page 43: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/43.jpg)
PAH: Traditional Therapy
Pharmacologic
– Calcium channel blocker
– Supplemental O2
– Anticoagulation (INR≈ 2-3)
– Diuretics (excessive preload)
– Digoxin
– IV inotropes (low dose dobutamine,
dopamine 1-2 mcg/kg/min)Rx for RV
failure}
![Page 44: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/44.jpg)
Diuretics
Treat edema May need combine therapy
![Page 45: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/45.jpg)
Anticoagulation
Studies only show benefit in iPAH patients Other PAH groups not as clear Aim for INR 2-2.5 Benefit thought to be Reduction of in-situ thrombosis Reduction DVT risk in low CO status
![Page 46: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/46.jpg)
Oxygen
Formal assessment of nocturnal and exertion oxygen levels
Minimal added insult of hypoxic vasocontriction
Aim to keep oxygen saturation > 90% Often impossible in large right to left shunt
patients
![Page 47: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/47.jpg)
Humbert M, et al. NEJM 2004; 351:1425-36.
![Page 48: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/48.jpg)
FDA-Approved Agents for theTreatment of PAH
Prostacyclin analogs (PA)– Epoprostenol– Iloprost– Treprostinil
Endothelin-receptor antagonists (ERA)– Bosentan– Ambrisentan
Phosphodiesterase-5 inhibitors (PDE-I)– Sildenafil– Tadalafil
![Page 49: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/49.jpg)
Endothelin Receptor Antagonist(ERA)
![Page 50: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/50.jpg)
Endothelin is increased in IPAH and PAH associated with other Diseases
Stewart et al., Ann Inter Med,1991 Vancheeswaran et al., J. Rheum, 1994 Yoshibayashi et al., Circulation, 1991
Congenital Heart Disease
Non-PH PH0
1
2
3
4
5 P<0.001
Del
ta E
T-L
I (P
V-R
V)
(pg/
ml)
IPAH
IrE
T-1
(pg
/ml)
Non-PPH PPH0
2
4
6
8
10
Scleroderma
Con
cent
ratio
n of
ET
-1(p
g/m
l)
4
6
8
10
LcSSc PAH
LcSSc Non-PAH
P<0.05P<0.001
![Page 51: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/51.jpg)
Endothelin is a Key Pathogenic Mediator*
Clozel. Ann Med. 2003
*Based on observations reported from in-vitro, in-vivo, or animal models. The clinical significance in humans is unknown.
Proliferation Vascular Smooth Muscle
Fibroblasts
Fibrosis Fibroblast Proliferation
Extracellular Matrix Proteins Collagenase Production
Inflammation Vascular Permeability
Neutrophil / Mast Cell Activation Promotes Cellular Adhesion
Cytokine Production
Hypertrophy Cardiac/Vascular
Vasoconstriction Direct Or Via Facilitation Of
Other Vasoconstrictor Systems (Renin
Angiotensin System, Sympathetic)ET
![Page 52: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/52.jpg)
Bosentan for PAH
Endothelin receptor antagonist (ETA/ETB non selective)
Indication – WHO group I - functional class II, III, IV
Dosage – 62.5 mg oral twice daily for 4 weeks then 125 mg oral twice daily
![Page 53: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/53.jpg)
62.5 mg bid 125 or 250 mg bid Bosentan
-40
-20
0
20
40
60
80
Bosentan (N = 144)
Placebo (N = 69)
Baseline Week 4 Week 8 Week 16
P = 0.0002
Cha
nge
from
Bas
elin
e (m
eter
s)
Rubin, et al. N Engl J Med. 2002;346:896-903.
Bosentan for PAH:BREATHE Clinical Trial
Change in 6-MWD (from Baseline to Week 16)
![Page 54: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/54.jpg)
Long-term outcomes on bosentan
Event rate/year (exponential): 5.5%
0 6 12 18 24 30 36 Time (Months )
169 167 163 153 113 23 16 Patients at risk
0
10
20
30
40
50
60
70
80
90
100
Cu
mu
lati
ve S
urv
ival
(%
)
Predicted (NIH)
Bosentan
69%57%
48%
96% 89% 86%
McLaughlin VV et al. Eur Respir J. 2005;25:244-249.
85% and 70% were on bosentan monotherapy at 12 and 24 mos, respectively
![Page 55: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/55.jpg)
Bosentan for PAH:EARLY Clinical Trial
Study design– Randomized, double-blind, placebo-controlled, six-month study
Patients– N = 177– Mildly-symptomatic PAH (WHO group II)
Study results– Primary study endpoints
• Decreased PVR (P < 0.0001)• No significant change in 6-MWD (P = 0.076)
– Secondary study endpoints• Delayed time to clinical worsening (P = 0.018; 70% reduction in risk)
– Safety• Consistent with previous studies
Galie, et al. Lancet. 2008.371(9630):2093-100.Valerio et al. Vasc Health Risk Manag. 2009;5:607-19.
![Page 56: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/56.jpg)
Bosentan for PAH:EARLY Clinical Trial
Change in PVR (from Baseline to Week 24)
Galie, et al. Lancet. 2008.371(9630):2093-100.Valerio et al. Vasc Health Risk Manag. 2009;5:607-19.
% o
f B
asel
ine
PV
R a
t W
eek
24(g
eom
etric
me
ans)
P < 0.0001
Decrease in PVR:Surrogate marker for
delaying disease progression
Treatment effect =- 22.6%
Treatment effect =- 22.6%
![Page 57: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/57.jpg)
Bosentan for PAH:EARLY Clinical Trial
10
5
0
5
10
15
20
12 24 weeks
Placebo (N= 91)
Bosentan (N= 86)P = 0.076
25
20
15
Change in 6-MWD (from Baseline to Week 24)
Treatment effect =+ 19.1 meters
Treatment effect =+ 19.1 meters
Cha
nge
in 6
-MW
D (
met
ers)
Galie, et al. Lancet. 2008.371(9630):2093-100.Valerio et al. Vasc Health Risk Manag. 2009;5:607-19.
11.2
- 7.9
weeks
![Page 58: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/58.jpg)
Bosentan for PAH:EARLY Clinical Trial
100
80
60
40
20
00 4 8 12 16 20 2824 32
92 90 89 86 84 83 1877 993 92 87 85 84 83 2780 15
Eve
nt-
Fre
e P
atie
nts
(%
)
Patients at risk (N)
Placebo
Bosentan
P < 0.02
Time to Clinical Worsening (from Baseline to Week 32)
weeksweeks
Galie, et al. Lancet. 2008.371(9630):2093-100.Valerio et al. Vasc Health Risk Manag. 2009;5:607-19.
![Page 59: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/59.jpg)
NTUH data
Bosentan have benefit effects on functional status, exercise capacity, right heart function and pulmonary function.
Respiratory Medicine 2007
![Page 60: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/60.jpg)
Ambrisentan for PAH
Endothelin receptor antagonist (ETA selective)
Indication – WHO group I - functional class II, III
Dosage – 5 mg and 10 mg oral daily
![Page 61: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/61.jpg)
Ambrisentan for PAH
Galie, et al. Circulation. 2008;117:3010-9.
-25
0
25
50
4 8 12 weeks
10 mg:+43.6 m
5 mg:+22.8 m
Placebo:-7.8 m
N = 202
4 8 12 weeks
5 mg:+49.4 m
2.5 mg+22.2 m
Placebo:-10.1 m
-20
0
20
40
60N = 192
Cha
nge
from
Bas
elin
e (m
eter
s)
ARIES 1 ARIES 2
Placebo-adjusted change at week 12:Ambrisentan 5 mg = 31 m; 10 mg = 51 m
Placebo-adjusted change at week 12:Ambrisentan 2.5 mg = 32 m; 5 mg = 59 m
Change in 6-MWD (from Baseline to Week 12)
![Page 62: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/62.jpg)
Endothelin Receptor AntagonistsComparison of Agents
Source: FDA-approved product labeling for individual agents. Source: FDA-approved product labeling for individual agents.
Bosentan Ambrisentan
Use in pregnancy
Pregnancy category X (non-hormonal birth control method required)
Pregnancy category X (non-hormonal birth control method required)
LFT elevation Monthly LFT monitoring required; ≥ 3x ULN in ~ 11% patients (pooled data from 16-week studies)
≥ 3x ULN in 0.8% patients in 12-week studies, 2.8% patients in 1-year studies
Peripheral edema
1.7% patients (placebo-adjusted; fluid retention/edema)
6% patients (placebo-adjusted)
Additional adverse events
Respiratory tract infections, headache, fainting, flushing, low blood pressure, sinusitis, joint pain, irregular heartbeat
Nasal congestion, sinusitis, flushing, palpitations, nasopharyngitis, abdominal pain, constipation
![Page 63: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/63.jpg)
Endothelin Receptor AntagonistsComparison of Drug-Drug Interactions
Source: FDA-approved product labeling for individual agents. 1) Barst, et al. J Am Coll Cardiol. 2009;54:S78-84. 2) Galie, et al. Eur Heart J. 2009;30:2493-2537. 3) Spence, et al. ATS. San Diego, CA.
May 15-20, 2009. 4) Harrison, et al. ATS. San Diego, CA. May 15-20, 2009.
Source: FDA-approved product labeling for individual agents. 1) Barst, et al. J Am Coll Cardiol. 2009;54:S78-84. 2) Galie, et al. Eur Heart J. 2009;30:2493-2537. 3) Spence, et al. ATS. San Diego, CA.
May 15-20, 2009. 4) Harrison, et al. ATS. San Diego, CA. May 15-20, 2009.
Bosentan Ambrisentan
Ritonavir
Rifampin
Cyclosporine A
Hormonal contraceptives
Sildenafil
Tadalafil1
Glyburide
Simvastatin (+ other CYP3A-metabolized statins)
CYP2C9 inhibitors (fluconazole, amiodarone)
CYP3A inhibitors (ketoconazole, itraconazole, amprenavir, erythromycin, fluconazole, diltiazem)
Tacrolimus
Phenytoin2
Warfarin2
Ritonavir
Rifampin
Cyclosporine A
Hormonal contraceptives3
Omeprazole4
Ketoconazole2,4
![Page 64: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/64.jpg)
Phosphodiesterase-5 inhibitors (PDE5-I)
![Page 65: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/65.jpg)
Sildenafil (Viagra, Revatio)
HypertensionHypertension
19819855 AnginaAngina
19891989
EEDD
19921992 19981998
PAHPAH
![Page 66: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/66.jpg)
L-Arginine Nitricoxide
cGMP Lowers PA
pressure
eNOS
GMP
PDE-5PDE-5I
PDE-5 located in pulmonary circulation PDE-5 responsible for cGMP hydrolysis in the lung cGMP appears to regulate pulmonary vascular tone and
growth PDE-5 inhibitor raises cGMP levels
Wharton J et al. Am J Respir Crit Care Med. 2005;172:105-113.
Nitric Oxide/ PDE-5 Inhibitors Increase cGMP
![Page 67: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/67.jpg)
SUPER-1 study
![Page 68: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/68.jpg)
REV-EM-0807001
![Page 69: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/69.jpg)
REV-EM-0807001
![Page 70: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/70.jpg)
Phosphodiesterase-5 InhibitorsComparison of Drug-Drug Interactions
Sildenafil TadalafilNitrates
Alpha blockers
Amlodipine
Ritonavir
Bosentan1
HMG CoA reductase inhibitors1
Phenytoin1
Erythromycin1
Ketoconazole1
Cimetidine1
Rifampin1
Phenobarbital1
Carbamazepine1
Nitrates
Alpha blockers
Antihypertensive agents
Ketoconazole
Rifampin
Ritonavir
Bosentan1
Source: FDA-approved product labeling for individual agents. 1) Galie, et al. Eur Heart J. 2009;30:2493-2537.Source: FDA-approved product labeling for individual agents. 1) Galie, et al. Eur Heart J. 2009;30:2493-2537.
![Page 71: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/71.jpg)
PROSTENOIDS
![Page 72: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/72.jpg)
SMC IP
PGI2PGI2
Smooth Muscle Cell relaxation
Inhibits SMC proliferation
? Apoptosis
Anti-thrombotic
GSGS
Adenylate cyclaseAdenylate cyclasecATPcATP
cAMPcAMP
Prostacyclins
![Page 73: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/73.jpg)
Inhalational Iloprost (Ventavis®) Approved for WHO Class III, IV patients with PAH
Properties: Selective pulmonary vasodilator Vasodilatory potency similar to PGI2 Exerts preferential vasodilation in well- ventilated lung
regions Longer duration of vasodilation than PGI2 (30-90 vs 15
min)
Prostenoid Analogue
![Page 74: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/74.jpg)
Ventavis® (iloprost) Inhalation Solution:
Dosage and Administration Indicated for inhalation via the Prodose® AAD® system only 2.5 mcg initial dose
– increase to 5 mcg if 2.5 mcg dose is tolerated
– maintain at maximum tolerable dose (2.5 mcg or 5 mcg) 6-9 inhalations daily during waking hours; 8-10 minutes each
![Page 75: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/75.jpg)
Iloprost for PAHComposite Primary Endpoint at Week 12
Olschewski, et al. N Engl J Med. 2002;347:322-9.
Res
pond
ers
(% P
atie
nts)
P = 0.0033
N = 203
![Page 76: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/76.jpg)
FLOLAN ® (epoprostenol): Synthetic prostenoid
Sodium epoprostenol (Flolan)--short-lived relatively locally acting vasodilator, t1/2 3-5 minutes.
Most potent effect -- cardiac output in patients with PAH
Resting heart rate, mean right atrial pressure, and a marked improvement in survival.
Abrupt cessation can be fatal Contraindicated in veno-occlusive disease
![Page 77: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/77.jpg)
CADD pump Central line
Epoprostenol for PAH
Prostacyclin analog Indication – WHO group I
- functional class III, IV Administration –
continuous IV infusion via central venous catheter
Dosage – 20-40 ng/kg/min
Storage – must keep medication cold with ice packs (stable for 8 hours at room temp)
![Page 78: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/78.jpg)
100
80
60
40
20
0Weeks
Epoprostenol (N = 41)
0 2 4 6 8 1210
Conventional therapy (N = 40)
Pat
ient
Sur
viva
l (%
)
P = 0.003P = 0.003
Barst, et al. N Engl J Med. 1996;334:296-301.
Epoprostenol vs. Conventional Therapy for IPAHPatient Survival
![Page 79: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/79.jpg)
Subcutaneous Treprostinil(Remodulin )
•SQ administration•Longer half-life than epoprostenol•Pre-mixed•Stable at room temperature
![Page 80: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/80.jpg)
Treprostinil SC for PAH
Change in 6-MWD (from Baseline to Week 12)
0
5
10
15
20
25
30
35
40
< 5.0ng/kg/min
5.0 - 8.1ng/kg/min
8.2 – 13.8ng/kg/min
> 13.8 ng/kg/min
3.31.4
20
36.1
Cha
nge
from
Bas
elin
e (m
eter
s)
P = 0.03
Simonneau, et al. Am J Respir Crit Care Med. 2002;165:800-4.
![Page 81: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/81.jpg)
Administration of Treprostinil
Subcutaneous Administration Continuous infusion using ambulatory
pump designed for SC infusions Self-inserted SC catheter Store at room temperature Change medication every 48 hours
(half-life > 4 hours)
Limitations Requires capable patient Possible pain (~ 85% of patients),
erythema, and induration at infusion site Mixed results with treatments for pain
(ice or heat, capsaicin, lidocaine patches, collagenase, NSAIDs, gabapentin, pregabalin, transdermal gels, low-dose narcotics)
Mini-Med
CADDms3
Infusion site reaction
![Page 82: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/82.jpg)
Which treatment is better ?
![Page 83: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/83.jpg)
Comparison of Agents
AgentRoute of
Administration Adverse Events
Epoprostenol Continuous IV infusion
Headache, jaw pain, flushing, nausea, diarrhea, skin rash, musculoskeletal pain
Iloprost Inhalation Headache, cough, flushing, jaw pain
Treprostinil » Subcutaneous
» IV
» Inhalation*
» Pain and erythema at injection site, headache, nausea, diarrhea, rash
» Headache, jaw pain, flushing, nausea, diarrhea, skin rash, musculoskeletal pain
» Cough, headache, flushing, throat irritation, nausea
Bosentan Oral Hepatotoxicity (LFT elevation ≥ 3x ULN ~ 11%), peripheral edema, anemia
Ambrisentan Oral Hepatotoxicity (LFT elevation ≥ 3x ULN ~ 2.8%), peripheral edema
Sildenafil Oral Headache, flushing, dyspepsia, epistaxis
Tadalafil Oral Headache, dyspepsia, back pain, myalgia, flushing
Adapted from McLaughlin, et al. J Am Coll Cardiol. 2009;53:1573-1619. *Benza, et al. ATS. San Diego, CA. May 15-20, 2009.
Adapted from McLaughlin, et al. J Am Coll Cardiol. 2009;53:1573-1619. *Benza, et al. ATS. San Diego, CA. May 15-20, 2009.
![Page 84: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/84.jpg)
ESC guidelines for PAH , Eur Heart J 2009;30: 2498-2537
![Page 85: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/85.jpg)
How do I evaluate the efficacy ?
![Page 86: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/86.jpg)
Parameters using in evaluation for treatment efficacy
• 6 minute-walking distance (MWD)• Cardiopulmonary exercising testing
– Peak oxygen uptake (V’O2)
• Hemodynamics– Cardiac index– Right atrial pressure
• Biomarkers– B-type natriuretic peptide (BNP)– N-terminal pro-BNP
![Page 87: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/87.jpg)
2006/04/10
Bosentan 62.5mg bid Symptom improved post 2 dose Keep treatment and F/U liver function one month later
(GOT/GPT: 48/55) Bosentan 125 mg bid 1 month later
![Page 88: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/88.jpg)
2007/03/21
Dilated RA,RV. RV hypertrophy Adequate LV performance. Moderate TR with
Pul.HTN<systolic PAP= 81mmHg>
Dilated PA with PR.
![Page 89: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/89.jpg)
2009
Function Class: IV -> I BNP: 52.9 pg/ml Radionuclide ventriculography :Right ventricular
Ejection Fraction: 72 % (normal range 45~70%)
![Page 90: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/90.jpg)
CXR
C/T ratio: 53 %
![Page 91: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/91.jpg)
![Page 92: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/92.jpg)
But……….
The patient suffered from progressive dyspnea since 2010/06
Syncope (+) Screening cardiac echo
– Estimated PAP > 200 mmHg
Admitted to ICU on 2010/07/02
![Page 93: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/93.jpg)
Critical PAH Patient
Cardiac arrest occurs frequently in critically ill patients with severe PAH.
Survival 90 days post-cardiac arrest was only 6 percent.
![Page 94: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/94.jpg)
PH and RV Failure: The Downward Spiral
Adaptation of Price lC et al. Crit Care. 2010;14:R169
HYPOTENSION
RVEDP
![Page 95: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/95.jpg)
Management Principles
Optimal volume status: avoid filling if RV volume overload, diuretics if necessary
Augment CO
Reduce PVR :
a) use pulmonary vasodilators
b)treat reversible factors that may increase PVR
Maintain adequate systemic pressure: Keep PVR well below SVR; use pressors if necessary
![Page 96: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/96.jpg)
Course of hospitalization
• ICU– Milrinone infusion– Diuretics for symptom– Bosentan 125mg bid po– Iloprost 5 mg q4h inhalation– Sildenafil 25mg tid po
• Symptom improved gradually• Shift iloprost to prn use• Discharge on 2010/07/13
– Bosentan 125mg bid + Sildenafil 25 mg tid + iloprost 5mg inhalation prn
![Page 97: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/97.jpg)
Mechanical Devices
Devices indication CommentsRV-assist devices Used in primary RV
dysfunction and have been used with coexisting
PH
Pulsatile devices may cause pulmonary
microcirculatory damage in PH . A pumpless "lung assist" device has been used in patients bridging
to transplant.
Extracorporeal membrane oxygenation
Used in severe PH as a bridge to lung transplant and after endarterectomy
or massive PE.
Intraaortic balloon counterpulsation
Used for RV failure after CPB and transplantation
Improves CO by augmenting left coronary flow rather than by direct
RV effects
Adaptation of Price lC et al. Crit Care. 2010;14:R169
![Page 98: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/98.jpg)
Case
55 y/o male Progressive dyspnea, leg edema and
hypotension Pulmonary hypertension was noted Transfer to CCU under the impression of
PAH with right heart failure complicated with shock and multiple organ failure
![Page 99: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/99.jpg)
Case 2se
11/21
Levophd
Primacor
11/25
illoprast
11/27
ECMO
CVVHD
11/30
Revatio
12/07
Remove ECMO
12/12
Stop CVVHD
1/25
Discharge
BP:89/65
sPA:90
BNP:721
Urine:1600
BP:56/46
sPA:90
Urine:115
BP:97/55 BP:127/73
Crea:1.21
ALT:33
Urine:345
BP:122/65
sPA:55
BNP:183
Crea:0.96
Urine:2935
BP:110/70
BNP:152
Crea:0.5
Urine:2060
![Page 100: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/100.jpg)
Diagnosis of PAH vasoreactivity test negative
Baseline exam and 3-6 monthly re-evaluation to assess treatment goals(Clinically stable, functional class II, 6-MWD > 400 meters, RAP/CI normal)
Treatment goals NOT met Treatment goals met
Start ERA or PDE-I
Add ERA or PDE-I
Parenteral PA and/or enrollment in clinical trials
Urgent lung transplantation
Continue treatment
Continue treatment
Continue treatment
Goal-Directed Therapy
Adapted from: Hoeper, et al. Eur Respir J. 2005;26:858-63.
![Page 101: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/101.jpg)
Improved Patient Survival With Goal-Directed Therapy
Hoeper, et al. Eur Respir J. 2005;26:858-63.
Cum
ulat
ive
Pat
ient
Sur
viva
l
1.0
0.8
0.6
0.4
0.2
0 6 12 18 24 30 36 Months
Patients at risk (N)
Treatment group
Historical control group
Treatment group(2002 -2004)
Historical control group(1999 -2001)
Expected survival
89
67
83
64
69
47
61
38
46
31
43
23
37
20
P = 0.011 Treatment Vs. historicalP < 0.001 Treatment Vs. expected
![Page 102: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/102.jpg)
Combination therapy: frequently utilised strategy in PAH treatment
Monotherapy (47%):• 13% bosentan\ambrisenten• 13% sildenafil• 8% epoprostenol• 2% sitaxentan• 4% calcium channel blocker
Dual combination (36%):
Background therapy only (8%)
Triple combination (9%)
McGoon, et al. Chest 2007; 132: 631S
Patients with PAH
n=1226
![Page 103: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/103.jpg)
NCKUH
![Page 104: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/104.jpg)
Bosentan + Sildenafil
Patients Dosing Results P
Mathai et al. 45 B 125 mg bid + S 20-100mg tid
6 MWD + 46 m NYHA improved in 5 of 13
0.05NS
Hoper et al. 9 B 125 mg bid +S 25-50mg tid
6MWD +115 mVO2 max +3.4 ml/min/kg
<0.0070.006
European 4996 Bosentan vs bosentan+sildenafil
Safety reports were similar
Early trial 29 S + B vs S + Placebo
Lower PVR 20.4%6MWD +17M
<0.05
0.855
![Page 105: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/105.jpg)
Bosentan + Prostacyclin
Combination Patients Result p
Hoper et al Bosentan+iloprost/beraprost
20 6 MWD +45 M <0.05
Channick et al.
Bosentan+treprostinil ih
11 6MWD +67MPAP-10%PVR-26%
0.010.0410.052
Benza RL et al.
SC remodulin + Bosentan
19 6 MWDBrog dyspneaPAP
0.0010.02<0.001
BREATH-2 Bosentan + Epo
33 PVR: 36 % vs 23 %
NS
STEP Bosentan+ iloprost
67 6MWDDelayed TCW
0.0510.022
![Page 106: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/106.jpg)
Prostacyclin+ PDE inhibitors
Combination Patients Result p
Ghofrani et al Iloprost+sildenafil
14 6 MWD +90 M 0.002
Goberg-Matiland M et al.
Treprostinil sc + sildenafil
TET time +42%
0.049
Ruiz MJ et al. Prostanoids+ sildenafil
20 6 MWD+79m (1 year)MWD +105m (2years)NYHA improved
<0.005
Simonneau G et al.
Epo+sildenafil
267 6MWD+26M TCW delay
0.00880.012
![Page 107: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/107.jpg)
CASE 3
38 y/o maleIPAH was diagnosed at 2008/8Bosentan used since
2008/8/19Add Iloprost since 2010/4/16
![Page 108: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/108.jpg)
6 minute walk test 6 minute walk test
2008/08/19 Bosentan375m 378m
350m
2010/4/16 Iloprost
320m
270m
![Page 109: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/109.jpg)
2011 RA : 18 RV : 52/24 PA : 54/46/39 PCWP : 9 Cardiac output:
2.46 L/min PVR : 15
woods
2008 RA:22 RV:55/32 PA:60/56/53 PCW: 15 Cardiac output:
6.7 L/min PVR: 6.1 woods
![Page 110: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/110.jpg)
Application Remodulin (2011/10/8) Discuss with patient about lung
transplant evaluation
![Page 111: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/111.jpg)
Remodulin daily recordRemodulin daily record
DoseBlood pressure
Site pain
Jaw pain
DiarreaHeadache
BNP NT-pro BNP
Day 1 2ng/kg/min 108/66 0 - - - 320 1890
Day 2 4ng/kg/min 108/64 2 - - -
Day 3 6ng/kg/min 97/58 3-4 - - - 256 1124
Day 4 8ng/kg/min 104/59 5 - - -
Day 5 10ng/kg/min 107/67 5 - - -
Day 6 12ng/kg/min 99/57 5-7 - - -
Day 7 14ng/kg/min 93/57 6 - - - 197 1214
Day 8 16ng/kg/min 94/63 6 - - -
Day 9 16ng/kg/min 89/54 6 - - -
Day 10 16ng/kg/min 97/56 6 - - -
Day 11 16ng/kg/min 94/58 6-8 - - -
Day 12 16ng/kg/min 95/59 6 - - - 191
Day 13 16ng/kg/min 94/59 2-3 mild - -
Day 14 16ng/kg/min 96/80 5 mild - -
![Page 112: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/112.jpg)
3 month later
NYHA Fc III =>II 6 minute walk distance: 347 m ( increase
28.5 %)
![Page 113: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/113.jpg)
Surgical Therapy
Transplantation - lung / heart-lung
• Reserved for patients who continue to
deteriorate with poor QOL despite
aggressive pharmacologic therapy
• 1 year survival - 65-70%
• 5 year survival - 40-50%
![Page 114: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/114.jpg)
Team work is necessary !!
![Page 115: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/115.jpg)
NCKUH Team Members
PAH- specific Cardiologist (PAH clinic, 24 hr on call)
Special nurse (24 hr on call) Radiologist Pharmacist Dietician Critical care team (24 hr on call) ECMO team (24 hr on call) Lung transplant team Lab
![Page 116: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/116.jpg)
Core member training
Whole member training
Multiple centereducation program
![Page 117: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/117.jpg)
How about the next five
year ?
![Page 118: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/118.jpg)
Investigational Treatments for PAH
Targeted Mechanism Investigational Agents
Prostacyclin Pathway
Iloprost
Treprostinil
Beraprost
Selexipeg
Endothelin Pathway Macisentan
Nitric Oxide Pathway Riociguat
Cicletanine
Growth Factors Signaling
Imatinib
Sorafenib
Aviptadil (Vasoactive intestinal peptide)
Cell Therapy Progenitor cells combined with gene
therapy
![Page 119: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/119.jpg)
Future Directions in PAH:Potential New Therapeutic Targets
Tyrosine kinase/growth factor receptor inhibitors (imatinib,sorafenib, nilotinib)
Vasoactive intestinal peptide (VIP) (aviptadil) Serotonin transporter agonists Tissue-targeting ERA (macitentan) Non-prostanoid IP receptor antagonist (selexipag) Adrenomedullin Rho-kinase inhibitors Nitric oxide enhancement (cicletanine) Soluble guanylate cyclase stimulator (riociguat) ECE/NEP inhibitor (daglutril) Monoclonal antibody to CD20 (rituximab) Endothelial progenitor cells Gene therapy (vectors expressing prostacyclin synthase, endothelial
NOS, or vascular endothelial growth factor )
![Page 120: 肺高壓的診斷與治療 國立成功大學附設醫院 許志新 醫師 2012/05/26, Tainan. What is PH ? What is PAH ?](https://reader031.vdocuments.mx/reader031/viewer/2022020712/551c3f3a55034693488b4a28/html5/thumbnails/120.jpg)
A cure for PAH ---is only a matter of time